MMAF （monomethyl auristatin F） is a new antimitotic auristatin derivative with a charged C-terminal phenylalanine residue.
Mc-VC-PAB-MMAF is a thiol reactive derivative of MMAF that contains a cathepsin B cleavable valine-citrulline p-aminobenzylcarbamate linkage （VC-PAB）.
This product is a control ADC for any IgG type antibody labeled with MMAF, particularly any ADC made using CellMosaic's Antibody MMAF Conjugation Kit （Cat#： CM11425 and Cat#： CM11422）.
The product uses a human IgG1 subtype antibody that does not bind to the target.
It has an average of 3-5 MMAF loaded on each antibody and can be used for accessing the effect of MMAF alone （non-specific toxicity）.
The product uses a very low endotoxin level antibody as a starting material （≤0.5 EU/mg by the LAL method）.
The preparation and purification are conducted under a pyrogen free environment.
The product is sold as 1 vial of 100 microgram （Cat# CM51101-100UG）, 1 vial of 500 micrograms （Cat# CM51101-500UG）, or 2 vials of 500 micrograms （Cat# CM51101-1MG）.
